Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57

Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and raises the price target from $53 to $57.